Bayer's Stock Rally Tests Patience as August Court Date and Debt Load Compete for Attention

Bayer shares fall 10.8% from 52-week high after Missouri court postpones fairness hearing for $7.25B glyphosate settlement, reintroducing legal uncertainty despite recent Supreme Court victory and restructuring moves.

Bayer's share price has been on a remarkable tear over the past 12 months, surging more than 72% as the company notched a major legal victory and pushed ahead with financial restructuring. But the ride is getting bumpier. After hitting a 52-week high of €53.86 in early July, the stock has pulled back 10.77% to close last week at €48.06 — a decline of 4.34% on the week. The reason? A delayed fairness hearing in Missouri that has reintroduced an unwelcome dose of uncertainty.

The hearing, originally scheduled for early July, will now take place on August 19 in a Missouri court. At stake is final approval of Bayer's $7.25 billion settlement covering a large portion of the outstanding glyphosate lawsuits in the United States. The postponement was announced by Bayer on July 18, and traders have since adopted a wait-and-see posture. With the annualized 30-day volatility sitting at 62.01%, the stock remains a play for strong stomachs only.

The legal landscape had brightened considerably earlier this year when the US Supreme Court ruled 7-2 that state-level cancer warning claims over glyphosate could be substantially hindered. That decision sent Bayer shares climbing 27.31% in the past month alone and prompted a flurry of analyst upgrades. JPMorgan reaffirmed its "Overweight" rating with a €50 target on July 17, while Barclays went further, lifting its target from €50 to €60 on July 14 and keeping an "Overweight" call. Berenberg raised its target to €55 from €40.50 on July 7, though it maintained a "Hold" rating, citing the improved prospects for a future breakup of the conglomerate. Jefferies remained more cautious, reiterating "Hold" with a €46 target on July 13.

Behind the courtroom drama, CEO Bill Anderson has been pushing a multi-pronged financial agenda. On July 17, Bayer completed the placement of $5 billion in new US-dollar bonds to refinance existing debt. A week earlier, the company secured €3 billion in equity from Apollo Global Management, giving Apollo-managed funds a minority stake in a new entity that houses Bayer's reversible long-acting contraceptive business. These moves are critical to funding the billion-dollar settlement payouts, but they also tie up capital that might otherwise flow into pharmaceuticals or seed technology.

Fitch Ratings took note of the balance sheet strain. On July 13, it affirmed Bayer's long-term issuer default rating at "BBB" but kept the outlook at "Negative", citing high net debt and persistent cash flow pressures. The message: the recent capital-raising steps have not fully resolved the company's structural financial concerns.

Chart watchers, however, see reasons for measured optimism. At €48.06, the stock trades 16.50% above its 50-day moving average of €41.25 and well above the 200-day average of €38.21 — a configuration that keeps the medium-term uptrend intact. If selling pressure intensifies, the €45 round number could come into play, but the more likely near-term range is €47 to €50 as the market marks time ahead of the hearing.

Beyond legal and financial headlines, Bayer is also laying groundwork for future growth. On July 15, the company signed an exclusive licensing agreement with French firm RAGT to develop hybrid wheat, with a commercial launch expected early in the next decade and revenue potential of €1 billion by the mid-2040s. Meanwhile, French asset manager Amundi disclosed on July 14 that it had crossed the 3% voting rights threshold, now holding an indirect 3.09% stake, or 30,375,174 voting rights.

Investors have a number of near-term milestones to track. The half-year report for the second quarter of 2026 is due on August 4, and the Missouri fairness hearing on August 19 will be the next major legal event. For now, Bayer's share price will continue to take its cues from the courtroom rather than the laboratory or the farm. Those who bought at the August 2025 low of €25.09 are sitting on a gain of 91.51% — proof that patience has paid off, but the next leg of the journey will require navigating a narrowly defined corridor of legal and financial risk.